The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Cyclooxygenase 2 Inhibitor Market Research Report 2024
Synopsis
COX inhibitors are mostly antipyretic and analgesic anti-inflammatory drugs, namely non-steroidal anti-inflammatory drugs (NSAIDs). COX-2 has extremely low activity in normal tissue cells, and can only be produced in large quantities when induced. It mediates pain, inflammation, and fever by promoting PG synthesis. In general, multiple adverse effects of non-steroidal anti-inflammatory drugs are believed to be related to the inhibition of COX-1. As a result, COX-2 selective inhibitors have emerged.
The global Cyclooxygenase 2 Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Cyclooxygenase 2 Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cyclooxygenase 2 Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Cyclooxygenase 2 Inhibitor in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Cyclooxygenase 2 Inhibitor include Pfizer, Bayer, Novartis, Merck, Sabinsa, Cadila Pharmaceuticals, Mylan, Teva Pharmaceutical and Alembic Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Cyclooxygenase 2 Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cyclooxygenase 2 Inhibitor.
Report Scope
The Cyclooxygenase 2 Inhibitor market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cyclooxygenase 2 Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cyclooxygenase 2 Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Bayer
Novartis
Merck
Sabinsa
Cadila Pharmaceuticals
Mylan
Teva Pharmaceutical
Alembic Pharmaceutical
Aurobindo Pharma
Cipla
Torrent Pharmaceuticals
Segment by Type
Selective Cox 2 Inhibitor
Non-Selective Cox 2 Inhibitor
Segment by Application
Hospital
Specialty Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cyclooxygenase 2 Inhibitor companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
COX inhibitors are mostly antipyretic and analgesic anti-inflammatory drugs, namely non-steroidal anti-inflammatory drugs (NSAIDs). COX-2 has extremely low activity in normal tissue cells, and can only be produced in large quantities when induced. It mediates pain, inflammation, and fever by promoting PG synthesis. In general, multiple adverse effects of non-steroidal anti-inflammatory drugs are believed to be related to the inhibition of COX-1. As a result, COX-2 selective inhibitors have emerged.
The global Cyclooxygenase 2 Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Cyclooxygenase 2 Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cyclooxygenase 2 Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Cyclooxygenase 2 Inhibitor in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Cyclooxygenase 2 Inhibitor include Pfizer, Bayer, Novartis, Merck, Sabinsa, Cadila Pharmaceuticals, Mylan, Teva Pharmaceutical and Alembic Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Cyclooxygenase 2 Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cyclooxygenase 2 Inhibitor.
Report Scope
The Cyclooxygenase 2 Inhibitor market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cyclooxygenase 2 Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cyclooxygenase 2 Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Bayer
Novartis
Merck
Sabinsa
Cadila Pharmaceuticals
Mylan
Teva Pharmaceutical
Alembic Pharmaceutical
Aurobindo Pharma
Cipla
Torrent Pharmaceuticals
Segment by Type
Selective Cox 2 Inhibitor
Non-Selective Cox 2 Inhibitor
Segment by Application
Hospital
Specialty Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cyclooxygenase 2 Inhibitor companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cyclooxygenase 2 Inhibitor Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Selective Cox 2 Inhibitor
1.2.3 Non-Selective Cox 2 Inhibitor
1.3 Market by Application
1.3.1 Global Cyclooxygenase 2 Inhibitor Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cyclooxygenase 2 Inhibitor Market Perspective (2019-2030)
2.2 Cyclooxygenase 2 Inhibitor Growth Trends by Region
2.2.1 Global Cyclooxygenase 2 Inhibitor Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cyclooxygenase 2 Inhibitor Historic Market Size by Region (2019-2024)
2.2.3 Cyclooxygenase 2 Inhibitor Forecasted Market Size by Region (2025-2030)
2.3 Cyclooxygenase 2 Inhibitor Market Dynamics
2.3.1 Cyclooxygenase 2 Inhibitor Industry Trends
2.3.2 Cyclooxygenase 2 Inhibitor Market Drivers
2.3.3 Cyclooxygenase 2 Inhibitor Market Challenges
2.3.4 Cyclooxygenase 2 Inhibitor Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cyclooxygenase 2 Inhibitor Players by Revenue
3.1.1 Global Top Cyclooxygenase 2 Inhibitor Players by Revenue (2019-2024)
3.1.2 Global Cyclooxygenase 2 Inhibitor Revenue Market Share by Players (2019-2024)
3.2 Global Cyclooxygenase 2 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cyclooxygenase 2 Inhibitor Revenue
3.4 Global Cyclooxygenase 2 Inhibitor Market Concentration Ratio
3.4.1 Global Cyclooxygenase 2 Inhibitor Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cyclooxygenase 2 Inhibitor Revenue in 2023
3.5 Cyclooxygenase 2 Inhibitor Key Players Head office and Area Served
3.6 Key Players Cyclooxygenase 2 Inhibitor Product Solution and Service
3.7 Date of Enter into Cyclooxygenase 2 Inhibitor Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cyclooxygenase 2 Inhibitor Breakdown Data by Type
4.1 Global Cyclooxygenase 2 Inhibitor Historic Market Size by Type (2019-2024)
4.2 Global Cyclooxygenase 2 Inhibitor Forecasted Market Size by Type (2025-2030)
5 Cyclooxygenase 2 Inhibitor Breakdown Data by Application
5.1 Global Cyclooxygenase 2 Inhibitor Historic Market Size by Application (2019-2024)
5.2 Global Cyclooxygenase 2 Inhibitor Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cyclooxygenase 2 Inhibitor Market Size (2019-2030)
6.2 North America Cyclooxygenase 2 Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cyclooxygenase 2 Inhibitor Market Size by Country (2019-2024)
6.4 North America Cyclooxygenase 2 Inhibitor Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cyclooxygenase 2 Inhibitor Market Size (2019-2030)
7.2 Europe Cyclooxygenase 2 Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cyclooxygenase 2 Inhibitor Market Size by Country (2019-2024)
7.4 Europe Cyclooxygenase 2 Inhibitor Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cyclooxygenase 2 Inhibitor Market Size (2019-2030)
8.2 Asia-Pacific Cyclooxygenase 2 Inhibitor Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cyclooxygenase 2 Inhibitor Market Size by Region (2019-2024)
8.4 Asia-Pacific Cyclooxygenase 2 Inhibitor Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cyclooxygenase 2 Inhibitor Market Size (2019-2030)
9.2 Latin America Cyclooxygenase 2 Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cyclooxygenase 2 Inhibitor Market Size by Country (2019-2024)
9.4 Latin America Cyclooxygenase 2 Inhibitor Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cyclooxygenase 2 Inhibitor Market Size (2019-2030)
10.2 Middle East & Africa Cyclooxygenase 2 Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cyclooxygenase 2 Inhibitor Market Size by Country (2019-2024)
10.4 Middle East & Africa Cyclooxygenase 2 Inhibitor Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Cyclooxygenase 2 Inhibitor Introduction
11.1.4 Pfizer Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Bayer
11.2.1 Bayer Company Detail
11.2.2 Bayer Business Overview
11.2.3 Bayer Cyclooxygenase 2 Inhibitor Introduction
11.2.4 Bayer Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024)
11.2.5 Bayer Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Cyclooxygenase 2 Inhibitor Introduction
11.3.4 Novartis Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Merck
11.4.1 Merck Company Detail
11.4.2 Merck Business Overview
11.4.3 Merck Cyclooxygenase 2 Inhibitor Introduction
11.4.4 Merck Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024)
11.4.5 Merck Recent Development
11.5 Sabinsa
11.5.1 Sabinsa Company Detail
11.5.2 Sabinsa Business Overview
11.5.3 Sabinsa Cyclooxygenase 2 Inhibitor Introduction
11.5.4 Sabinsa Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024)
11.5.5 Sabinsa Recent Development
11.6 Cadila Pharmaceuticals
11.6.1 Cadila Pharmaceuticals Company Detail
11.6.2 Cadila Pharmaceuticals Business Overview
11.6.3 Cadila Pharmaceuticals Cyclooxygenase 2 Inhibitor Introduction
11.6.4 Cadila Pharmaceuticals Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024)
11.6.5 Cadila Pharmaceuticals Recent Development
11.7 Mylan
11.7.1 Mylan Company Detail
11.7.2 Mylan Business Overview
11.7.3 Mylan Cyclooxygenase 2 Inhibitor Introduction
11.7.4 Mylan Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024)
11.7.5 Mylan Recent Development
11.8 Teva Pharmaceutical
11.8.1 Teva Pharmaceutical Company Detail
11.8.2 Teva Pharmaceutical Business Overview
11.8.3 Teva Pharmaceutical Cyclooxygenase 2 Inhibitor Introduction
11.8.4 Teva Pharmaceutical Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024)
11.8.5 Teva Pharmaceutical Recent Development
11.9 Alembic Pharmaceutical
11.9.1 Alembic Pharmaceutical Company Detail
11.9.2 Alembic Pharmaceutical Business Overview
11.9.3 Alembic Pharmaceutical Cyclooxygenase 2 Inhibitor Introduction
11.9.4 Alembic Pharmaceutical Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024)
11.9.5 Alembic Pharmaceutical Recent Development
11.10 Aurobindo Pharma
11.10.1 Aurobindo Pharma Company Detail
11.10.2 Aurobindo Pharma Business Overview
11.10.3 Aurobindo Pharma Cyclooxygenase 2 Inhibitor Introduction
11.10.4 Aurobindo Pharma Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024)
11.10.5 Aurobindo Pharma Recent Development
11.11 Cipla
11.11.1 Cipla Company Detail
11.11.2 Cipla Business Overview
11.11.3 Cipla Cyclooxygenase 2 Inhibitor Introduction
11.11.4 Cipla Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024)
11.11.5 Cipla Recent Development
11.12 Torrent Pharmaceuticals
11.12.1 Torrent Pharmaceuticals Company Detail
11.12.2 Torrent Pharmaceuticals Business Overview
11.12.3 Torrent Pharmaceuticals Cyclooxygenase 2 Inhibitor Introduction
11.12.4 Torrent Pharmaceuticals Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024)
11.12.5 Torrent Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Cyclooxygenase 2 Inhibitor Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Selective Cox 2 Inhibitor
Table 3. Key Players of Non-Selective Cox 2 Inhibitor
Table 4. Global Cyclooxygenase 2 Inhibitor Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Cyclooxygenase 2 Inhibitor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Cyclooxygenase 2 Inhibitor Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Cyclooxygenase 2 Inhibitor Market Share by Region (2019-2024)
Table 8. Global Cyclooxygenase 2 Inhibitor Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Cyclooxygenase 2 Inhibitor Market Share by Region (2025-2030)
Table 10. Cyclooxygenase 2 Inhibitor Market Trends
Table 11. Cyclooxygenase 2 Inhibitor Market Drivers
Table 12. Cyclooxygenase 2 Inhibitor Market Challenges
Table 13. Cyclooxygenase 2 Inhibitor Market Restraints
Table 14. Global Cyclooxygenase 2 Inhibitor Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Cyclooxygenase 2 Inhibitor Market Share by Players (2019-2024)
Table 16. Global Top Cyclooxygenase 2 Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cyclooxygenase 2 Inhibitor as of 2023)
Table 17. Ranking of Global Top Cyclooxygenase 2 Inhibitor Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Cyclooxygenase 2 Inhibitor Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Cyclooxygenase 2 Inhibitor Product Solution and Service
Table 21. Date of Enter into Cyclooxygenase 2 Inhibitor Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Cyclooxygenase 2 Inhibitor Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Cyclooxygenase 2 Inhibitor Revenue Market Share by Type (2019-2024)
Table 25. Global Cyclooxygenase 2 Inhibitor Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Cyclooxygenase 2 Inhibitor Revenue Market Share by Type (2025-2030)
Table 27. Global Cyclooxygenase 2 Inhibitor Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Cyclooxygenase 2 Inhibitor Revenue Market Share by Application (2019-2024)
Table 29. Global Cyclooxygenase 2 Inhibitor Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Cyclooxygenase 2 Inhibitor Revenue Market Share by Application (2025-2030)
Table 31. North America Cyclooxygenase 2 Inhibitor Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Cyclooxygenase 2 Inhibitor Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Cyclooxygenase 2 Inhibitor Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Cyclooxygenase 2 Inhibitor Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Cyclooxygenase 2 Inhibitor Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Cyclooxygenase 2 Inhibitor Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Cyclooxygenase 2 Inhibitor Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Cyclooxygenase 2 Inhibitor Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Cyclooxygenase 2 Inhibitor Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Cyclooxygenase 2 Inhibitor Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Cyclooxygenase 2 Inhibitor Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Cyclooxygenase 2 Inhibitor Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Cyclooxygenase 2 Inhibitor Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Cyclooxygenase 2 Inhibitor Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Cyclooxygenase 2 Inhibitor Market Size by Country (2025-2030) & (US$ Million)
Table 46. Pfizer Company Detail
Table 47. Pfizer Business Overview
Table 48. Pfizer Cyclooxygenase 2 Inhibitor Product
Table 49. Pfizer Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024) & (US$ Million)
Table 50. Pfizer Recent Development
Table 51. Bayer Company Detail
Table 52. Bayer Business Overview
Table 53. Bayer Cyclooxygenase 2 Inhibitor Product
Table 54. Bayer Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024) & (US$ Million)
Table 55. Bayer Recent Development
Table 56. Novartis Company Detail
Table 57. Novartis Business Overview
Table 58. Novartis Cyclooxygenase 2 Inhibitor Product
Table 59. Novartis Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024) & (US$ Million)
Table 60. Novartis Recent Development
Table 61. Merck Company Detail
Table 62. Merck Business Overview
Table 63. Merck Cyclooxygenase 2 Inhibitor Product
Table 64. Merck Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024) & (US$ Million)
Table 65. Merck Recent Development
Table 66. Sabinsa Company Detail
Table 67. Sabinsa Business Overview
Table 68. Sabinsa Cyclooxygenase 2 Inhibitor Product
Table 69. Sabinsa Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024) & (US$ Million)
Table 70. Sabinsa Recent Development
Table 71. Cadila Pharmaceuticals Company Detail
Table 72. Cadila Pharmaceuticals Business Overview
Table 73. Cadila Pharmaceuticals Cyclooxygenase 2 Inhibitor Product
Table 74. Cadila Pharmaceuticals Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024) & (US$ Million)
Table 75. Cadila Pharmaceuticals Recent Development
Table 76. Mylan Company Detail
Table 77. Mylan Business Overview
Table 78. Mylan Cyclooxygenase 2 Inhibitor Product
Table 79. Mylan Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024) & (US$ Million)
Table 80. Mylan Recent Development
Table 81. Teva Pharmaceutical Company Detail
Table 82. Teva Pharmaceutical Business Overview
Table 83. Teva Pharmaceutical Cyclooxygenase 2 Inhibitor Product
Table 84. Teva Pharmaceutical Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024) & (US$ Million)
Table 85. Teva Pharmaceutical Recent Development
Table 86. Alembic Pharmaceutical Company Detail
Table 87. Alembic Pharmaceutical Business Overview
Table 88. Alembic Pharmaceutical Cyclooxygenase 2 Inhibitor Product
Table 89. Alembic Pharmaceutical Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024) & (US$ Million)
Table 90. Alembic Pharmaceutical Recent Development
Table 91. Aurobindo Pharma Company Detail
Table 92. Aurobindo Pharma Business Overview
Table 93. Aurobindo Pharma Cyclooxygenase 2 Inhibitor Product
Table 94. Aurobindo Pharma Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024) & (US$ Million)
Table 95. Aurobindo Pharma Recent Development
Table 96. Cipla Company Detail
Table 97. Cipla Business Overview
Table 98. Cipla Cyclooxygenase 2 Inhibitor Product
Table 99. Cipla Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024) & (US$ Million)
Table 100. Cipla Recent Development
Table 101. Torrent Pharmaceuticals Company Detail
Table 102. Torrent Pharmaceuticals Business Overview
Table 103. Torrent Pharmaceuticals Cyclooxygenase 2 Inhibitor Product
Table 104. Torrent Pharmaceuticals Revenue in Cyclooxygenase 2 Inhibitor Business (2019-2024) & (US$ Million)
Table 105. Torrent Pharmaceuticals Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cyclooxygenase 2 Inhibitor Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Cyclooxygenase 2 Inhibitor Market Share by Type: 2023 VS 2030
Figure 3. Selective Cox 2 Inhibitor Features
Figure 4. Non-Selective Cox 2 Inhibitor Features
Figure 5. Global Cyclooxygenase 2 Inhibitor Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Cyclooxygenase 2 Inhibitor Market Share by Application: 2023 VS 2030
Figure 7. Hospital Case Studies
Figure 8. Specialty Clinic Case Studies
Figure 9. Others Case Studies
Figure 10. Cyclooxygenase 2 Inhibitor Report Years Considered
Figure 11. Global Cyclooxygenase 2 Inhibitor Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Cyclooxygenase 2 Inhibitor Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Cyclooxygenase 2 Inhibitor Market Share by Region: 2023 VS 2030
Figure 14. Global Cyclooxygenase 2 Inhibitor Market Share by Players in 2023
Figure 15. Global Top Cyclooxygenase 2 Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cyclooxygenase 2 Inhibitor as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Cyclooxygenase 2 Inhibitor Revenue in 2023
Figure 17. North America Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Cyclooxygenase 2 Inhibitor Market Share by Country (2019-2030)
Figure 19. United States Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Cyclooxygenase 2 Inhibitor Market Share by Country (2019-2030)
Figure 23. Germany Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Cyclooxygenase 2 Inhibitor Market Share by Region (2019-2030)
Figure 31. China Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Cyclooxygenase 2 Inhibitor Market Share by Country (2019-2030)
Figure 39. Mexico Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Cyclooxygenase 2 Inhibitor Market Share by Country (2019-2030)
Figure 43. Turkey Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Cyclooxygenase 2 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Pfizer Revenue Growth Rate in Cyclooxygenase 2 Inhibitor Business (2019-2024)
Figure 46. Bayer Revenue Growth Rate in Cyclooxygenase 2 Inhibitor Business (2019-2024)
Figure 47. Novartis Revenue Growth Rate in Cyclooxygenase 2 Inhibitor Business (2019-2024)
Figure 48. Merck Revenue Growth Rate in Cyclooxygenase 2 Inhibitor Business (2019-2024)
Figure 49. Sabinsa Revenue Growth Rate in Cyclooxygenase 2 Inhibitor Business (2019-2024)
Figure 50. Cadila Pharmaceuticals Revenue Growth Rate in Cyclooxygenase 2 Inhibitor Business (2019-2024)
Figure 51. Mylan Revenue Growth Rate in Cyclooxygenase 2 Inhibitor Business (2019-2024)
Figure 52. Teva Pharmaceutical Revenue Growth Rate in Cyclooxygenase 2 Inhibitor Business (2019-2024)
Figure 53. Alembic Pharmaceutical Revenue Growth Rate in Cyclooxygenase 2 Inhibitor Business (2019-2024)
Figure 54. Aurobindo Pharma Revenue Growth Rate in Cyclooxygenase 2 Inhibitor Business (2019-2024)
Figure 55. Cipla Revenue Growth Rate in Cyclooxygenase 2 Inhibitor Business (2019-2024)
Figure 56. Torrent Pharmaceuticals Revenue Growth Rate in Cyclooxygenase 2 Inhibitor Business (2019-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
